inPractice® - ACTG 5095

Special Considerations in the Management of HIV-Infected Patients From Minority Communities

Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
Section Editor: Judith S. Currier, MD, MSc
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 7/9/18 (What's New)

Summary

ACTG 5095 compared (zidovudine/lamivudine plus either abacavir, efavirenz, or both abacavir and efavirenz) in antiretroviral-naive patients^{[Gulick 2004]}
Study population was 36% blacks, 21% Latinos, and 40% non-Latino whites
Blacks had a shorter time to virologic failure than whites in the efavirenz-containing arms^{[Gulick 2006]}

Polymorphism in the CYP2B6 Gene

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Initial Antiretroviral Therapy, Minority-Ethnic Communities, Pharmacokinetics, Special Populations